Fig. 3

Influence of Selinexor on plasma cell and CAR T-cell in vitro. a, b Flow cytometry was used to assess the viability of CAR-T (CT103A) cells and NT (negative control) cells in different concentrations of Selinexor (0-100 nM). There was no difference observed between different dose groups. c, d Flow cytometry was used to assess the viability of MM1S and U266 cell lines in different concentrations of Selinexor (0-100 nM). No difference was observed between different dose groups. e–g Flow cytometry was used to evaluate MFI and expression rate of BCMA on MM1S and U266 cell lines pre-treated with different concentrations of Selinexor (0-100 nM). There was a slight but not statistically significant increase in MFI. Meanwhile, there was a significant increase of expression rate of surface BCMA with dose escalation. h Flow cytometry was used to assess the viability of different concentrations of Selinexor (0-100 nM) pre‑treated MM1S and U266 cell lines when co-cultured with CAR-T cells. i The statistical representation of diagram h. The cytotoxicity increased in a dose-dependent manner, which was statistically significant. Abbreviations: BCMA, B cell maturation antigen; MFI, mean fluorescence intensity; ns, no significance; XPO-1, nuclear export protein 1 inhibitor Selinexor. *Statistically significant with p < 0.05, **p < 0.01, and ***p < 0.0001